1584. In Vitro Activity of Imipenem/Relebactam against Gram-Negative Pathogens from Patients with Bloodstream Infections in the United States and Canada – SMART 2018

BACKGROUND: Relebactam (REL) inhibits class A and C β-lactamases, including KPC, and was approved in the United States combined with imipenem (IMI) and cilastatin for complicated urinary tract and intraabdominal infections. We evaluated the activity of IMI/REL against non-Morganellaceae (NME) and P....

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Open Forum Infect Dis
मुख्य लेखकों: Lob, Sibylle, Hackel, Meredith, Young, Katherine, Motyl, Mary, Sahm, Daniel F
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Oxford University Press 2020
विषय:
Poster Abstracts
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC7777755/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa439.1764
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन